Avenue Therapeutics, Inc.

Historical 13F Holders

Reported Value, Excluding Options

Total Filings

Investors who own more than 5% of a class must file a Schedule 13D or 13G. Each filer's latest filing for 05360L403 since 12/18/2024, largest first.

Filer	% of Class	Shares	Form	Filed
Fortress Biotech, Inc. 13D/A	13.4%	439,955	13D/A	1/6/2026 Event 1/2/2026
Under 5%, checked the "5 percent or less" box, or amended by a later filing (2)
Armistice Capital, LLC 13G/A	4.99%	100,400	13G/A	2/14/2025 Event 12/31/2024
Armistice Capital, LLC	4.99%	100,400
Steven Boyd	4.99%	100,400
Ikarian Capital, LLC 13G/A	4.1%	130,820	13G/A	2/17/2026 Event 12/31/2025
Ikarian Capital, LLC	4.1%	130,820
Neil Shahrestani	4.1%	130,820

Period	Filings	Shares, Excl. Options	Value, Excl. Options	Options Value
2024 Q4	8	193 k	$385 k	$0
2024 Q3	10	198 k	$492 k	$0
2024 Q2	11	116 k	$407 k	$0